GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » EV-to-FCF

Prenetics Global (Prenetics Global) EV-to-FCF : (As of May. 03, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prenetics Global's Enterprise Value is $-5.32 Mil. Prenetics Global's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Prenetics Global's EV-to-FCF for today is .

The historical rank and industry rank for Prenetics Global's EV-to-FCF or its related term are showing as below:

PRE' s EV-to-FCF Range Over the Past 10 Years
Min: -15.8   Med: -3.05   Max: 297.35
Current: -0.65

During the past 5 years, the highest EV-to-FCF of Prenetics Global was 297.35. The lowest was -15.80. And the median was -3.05.

PRE's EV-to-FCF is ranked better than
98.08% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.875 vs PRE: -0.65

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Prenetics Global's stock price is $5.23. Prenetics Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.920. Therefore, Prenetics Global's PE Ratio for today is At Loss.


Prenetics Global EV-to-FCF Historical Data

The historical data trend for Prenetics Global's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global EV-to-FCF Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - 12.59 -

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.59 - - - -

Competitive Comparison of Prenetics Global's EV-to-FCF

For the Diagnostics & Research subindustry, Prenetics Global's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Prenetics Global's EV-to-FCF falls into.



Prenetics Global EV-to-FCF Calculation

Prenetics Global's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-5.318/0
=

Prenetics Global's current Enterprise Value is $-5.32 Mil.
Prenetics Global's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prenetics Global  (NAS:PRE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Prenetics Global's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.23/-5.920
=At Loss

Prenetics Global's share price for today is $5.23.
Prenetics Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.920.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Prenetics Global EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Prenetics Global's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.